Antidepressants exert distinct effects on cardiac autonomic nervous system function depending on their receptor profile; thus, different groups of antidepressants are expected to inşuence cardiac parameters in varying degrees. This study compares the effects of venlafaxine, a serotonin and noradrenaline reuptake inhibitor and reboxetine, a selective noradrenaline reuptake inhibitor, on ECG parameters and vital signs.
Methods: The cardiac parameters and vital signs of 44 depressed patients were evaluated. The initial dose of venlafaxine XR was 75 mg/day and the dose was increased to 150 mg/day at the end of the 2nd week. Reboxetine was started at 4 mg/day and increased to 8 mg/day at the end of the 2nd week of the study. Electrocardiography (ECG) was performed and the PR, QRS, QT, and QTc intervals were measured both at the beginning and at the end of the trial, as were the vital signs.
Results: The heart rate was significantly increased in the reboxetine group (Wilcoxon z=-3.510, p
QTc interval, venlafaxine, reboxetine, depression, heart rate